ARTICLE | Company News
Pulmagen, Teijin deal
October 1, 2012 7:00 AM UTC
Pulmagen granted Teijin exclusive rights to develop and commercialize ADC3680 in Japan. Teijin plans to start Phase I testing of ADC3680 in Japan in April 2013 for asthma. The oral small molecule pro...